| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000002964 |
| Receipt No. | R000003436 |
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties |
| Date of disclosure of the study information | 2010/01/03 |
| Last modified on | 2018/05/24 (Ver. 5) |
| Basic information | ||
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties | |
| Title of the study (Brief title) | Prospective, randomized, open-label, clinical trial comparing fibrate monotherapy and fibrate-ezetimibe combination therapy | |
| Region |
|
|
| Condition | ||
| Condition | dyslipidemia | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Comparison of fibrate monotherapy and fibrate-ezetimibe combination therapy on progression of atherosclerotic plaques, endothelial function, and markers for anti-inflammatory properties/obesity/antioxidative properties |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase IV |
| Assessment | |
| Primary outcomes | Area of atherosclerotic plaques in aorta detected by magnetic resonance imaging (MRI), 12/24 months after randomization
Serum lipids (total/LDL/HDL-cholesterol, triglycerides), 6/12/24 months after randomization Flow-mediated vasodilation in forearm, 6 months after randomization Heparin-releasable EC-SOD levels, 6 months after randomization |
| Key secondary outcomes | Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria), 6/12/24 months after randomization |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of ezetimibe | |
| Interventions/Control_2 | No medication | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Dyslipidemic patients under treatment with fibrates, whose LDL-C levels do not meet those recommended by Japan Atherosclerosis Society Guidelines for prevention of Atherosclerotic Cardiovascular Disease.
2) Patients who have aortic atherosclerotic plaques detected by MRI 3) Outpatients 4) Subjects who gave written informed consent |
|||
| Key exclusion criteria | 1) Allergy against ezetimibe
2) Under treatment with statins 3) Poor-controlled hypertension (DBP>110 mmHg) 4) Poor-controlled diabetes (HbA1c>10.0 %) 5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 6) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 7) Chronic renal failure (serum creatinine>2.0 mg/dl) 8) Malignancies or other diseases with poor prognosis 9) Pregnant 10) Subjects whose doctor in charge do not agree to join the trial |
|||
| Target sample size | 60 | |||
| Research contact person | |
| Name of lead principal investigator | Katsunori Ikewaki |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine I |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1597 |
| katsunorike@ndmc.ac.jp | |
| Public contact | |
| Name of contact person | Makoto Ayaori |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine I |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1597 |
| Homepage URL | |
| ayaori@ndmc.ac.jp | |
| Sponsor | |
| Institute | National Defense Medical College |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Foundation for Promotion of Defense Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 防衛医科大学校 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003436 |